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The aim of the present study was to examine whether endocannabinoids cause PPARγ-mediated vascular actions. Functional vas-
cularstudieswerecarriedoutinrataortae.AnandamideandN-arachidonoyl-dopamine(NADA),butnotpalmitoylethanolamide,
causedsigniﬁcantvasorelaxationovertime(2hours).VasorelaxationtoNADA,butnotanandamide,wasinhibitedbyCB1 receptor
antagonism (AM251, 1μM), and vasorelaxation to both anandamide and NADA was inhibited by PPARγ antagonism (GW9662,
1μM). Pharmacological inhibition of de novo protein synthesis, nitric oxide synthase, and super oxide dismutase abolished the
responses to anandamide and NADA. Removal of the endothelium partly inhibited the vasorelaxant responses to anandamide
and NADA. Inhibition of fatty acid amide hydrolase (URB597, 1μM) inhibited the vasorelaxant response to NADA, but not
anandamide. These data indicate that endocannabinoids cause time-dependent, PPARγ-mediated vasorelaxation. Activation of
PPARγ in the vasculature may represent a novel mechanism by which endocannabinoids are involved in vascular regulation.
Copyright © 2009 Saoirse E. O’Sullivan et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Peroxisome proliferator-activated receptors (PPARs) are
nuclear receptors which control the transcription of many
families of genes. They have a large ligand binding pocket
and are pharmacologically promiscuous, being activated
by a number of structurally diverse natural and synthetic
ligands including some angiotensin II receptor antagonists
[1], statins [2], retinoic receptor antagonists [3], ﬂavinoids
[4], and citrus fruit compounds [5]. An increasing body
of evidence now also suggests that cannabinoids activate
PPARs, and this may mediate some of the biological eﬀects
of cannabinoids [6], in addition to activation of two well-
established 7-transmembrane cannabinoid receptors (CB1
and CB2).
TheﬁrstevidenceofcannabinoidinteractionswithPPAR
came in 2002 in a study by Kozak and colleagues who
showed that lipoxygenase metabolism of the endocannabi-
noid, 2-arachidonoylglycerol (2-AG), produced a metabolite
that increases the transcriptional activity of PPARα [7].
Fu et al. (2003) then showed that the appetite-suppressing
and weight-reducing eﬀects of another endocannabinoid-
related agent, oleoylethanolamide (OEA), were absent in
PPARα knock-out mice [8]. Guzm´ an et al. (2004) also
showed that the stimulatory eﬀect of OEA on lipolysis
in vivo was absent in PPARα knock-out mice [9]. Palmi-
toylethanolamide (PEA), which is structurally related to
OEA,similarlyactivatesPPARαtranscriptionalactivity,caus-
ing anti-inﬂammatory actions that were absent in PPARα
knock-out mice [10]. Other endocannabinoids that have
been shown to activate PPARα include noladin ether and
virodhamine [11].
As well as activating PPARα, it was shown in 2003 [12]
that the synthetic cannabinoid, ajulemic acid (an analogue
of a tetrahydrocannabinol metabolite) binds to and increases
the transcriptional activity of PPARγ.W eh a v es i n c es h o w n
that the principal active ingredient of Cannabis sativa, Δ9-
tetrahydrocannabinol (THC), activates the transcriptional
activity of PPARγ and stimulates adipogenesis, a PPARγ
property[13].Theendocannabinoidsanandamideand2-AG
have anti-inﬂammatory eﬀects which are sensitive to PPARγ
antagonism [14, 15], although it was not clear whether these2 PPAR Research
eﬀects were through activation of PPARγ directly, or via
metabolites of the endocannabinoids. Subsequent research
has shown that anandamide directly binds to PPARγ [16,
17], activates PPARγ transcriptional activity, and stimu-
lates the diﬀerentiation of ﬁbroblasts to adipocytes [16].
Other cannabinoids that activate the transcriptional activity
of PPARγ include the endocannabinoid/endovanilloid, N-
arachidonoyl-dopamine (NADA), the synthetic cannabi-
noids WIN55212-2 and CP55940, and the phytocannabi-
noid, cannabidiol [18].
We have shown that THC causes time-dependent,
endothelium-dependent, PPARγ-mediated vasorelaxation of
the rat isolated aorta [13]. This response was dependent on
nitric oxide (NO) and superoxide dismutase (SOD) activity
[13]. Furthermore, subsequent studies showed that 2-hour
incubation with THC (10μM) in vitro blunts subsequent
contractile responses and enhances vasodilator responses in
isolated arteries, which was also inhibited by a PPARγ antag-
onist [19]. These experiments similarly indicated a role for
increased SOD activity stimulated by THC. Together, these
studiessuggestthatTHC,throughactivationofPPARγ,leads
to increased synthesis of SOD, promoting vasorelaxation by
preventing NO being scavenged by endogenous superoxides.
This is in agreement with research showing that, in addition
to direct eﬀects on NO production, PPARγ ligands enhance
NO bioavailability in blood vessels through induction of
SOD [20].
There has been much interest surrounding the vascular
actions of endocannabinoids. The mechanisms underpin-
ning the acute vasorelaxant response to endocannabinoids
include activation of sensory nerves [21–23], activation of
the CB1 receptor, and activation of a novel endothelial
cannabinoid receptor [23–25]. In light of the growing
evidence that endocannabinoids activate PPARγ [14–18],
the aim of the present study was to investigate whether
similar time-dependent, PPARγ-mediated vasorelaxation to
endocannabinoids occurs in the rat aorta as observed for
THC, and to investigate the underlying mechanisms.
2.MaterialandMethods
2.1. In Vitro Vascular Studies. Male Wistar rats (250–350g)
were stunned by a blow to the back of the head and
killed by cervical dislocation. The aortae were removed
rapidly and placed into cold modiﬁed Krebs-Henseleit
buﬀer (composition, mM: NaCl 118, KCl 4.7, MgSO4 1.2,
KH2PO4 1.2, NaHCO3 25, CaCl2 2, and D-glucose 10).
The aortae were dissected free of adherent connective and
adipose tissue and cut into rings 3-4mm long, and mounted
on ﬁxed segment support pins using the Multimyograph
system (Model 610M, Danish Myo Technology, Denmark) as
previously described [13, 19, 23]. Once mounted, all vessels
were kept at 37◦C in modiﬁed Krebs-Henseleit buﬀer and
gassed with 5% CO2 in O2. The aortae were stretched to
an optimal passive tension of 9.8mN tension. Vessels were
allowed to equilibrate and the contractile integrity of each
was tested by its ability to contract to 60mM KCl by at
least 4.9mN. Vessels were contracted with a combination
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Figure 1: The mean vasorelaxant response to (a) AEA, (b)
NADA, and (c) PEA versus vehicle (0.1% EtOH) over 2 hours
in preconstricted aortae. Data are given as means with error bars
representing SEM. (∗P<. 05, ∗∗P<. 01, Student’s t-test, n = 12).PPAR Research 3
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Figure 2: The eﬀects of the CB1 receptor antagonist AM251 (1μM, (a), and (b)) and the CB2 receptor antagonist AM630 (1μM, (c), and
(d))on vasorelaxation to anandamide and NADA. Data aregiven as means with error bars representing SEM. (∗P<. 05, ∗∗P<. 01, Student’s
t-test.)
of U46619 (10–100nM, a thromboxane prostanoid receptor
agonist), and the α-adrenoceptor agonist methoxamine (1–
5μM) to increase tension.
When stable contraction was maintained, the vasorelax-
ant eﬀect of a single concentration of endocannabinoid or
vehicle control (0.1% ethanol) on induced tone was assessed
as the reduction in tone over time. The endocannabinoids
chosen were anandamide (5μM) and NADA (10μM), both
previously demonstrated to be PPARγ ligands [14, 16–18],
and PEA (10μM), which activates PPARα but not PPARγ
[10]. For every experimental protocol, vehicle-treated and
endocannabinoid-treated experiments were performed in
adjacent segments of the same artery.
To assess any possible contribution of vasorelaxation
mediated through cannabinoid receptors, some experiments
were performed in the presence of the cannabinoid CB1
receptor antagonist AM251 (1μM), or the CB2 receptor
antagonist AM630 (1μM), both added 10 minutes before
contracting the vessels.
To assess the contribution of PPARγ activation, some
experiments were performed in the presence of the PPARγ
antagonist GW9662 (1μM) added 10 minutes prior to
precontraction. To establish whether the time-dependent
vasorelaxant eﬀects of endocannabinoids were dependent
upon de novo protein synthesis, some experiments were
performed in the presence of the protein synthesis inhibitor
cycloheximide (10μM).
To investigate the role of endothelium-derived relaxing
factors in the time-dependent vasorelaxation to endo-
cannabinoids, some vessels were denuded of their endothe-
lium by abrasion with a human hair. The role of
endothelium-derived nitric oxide (NO) was investigated
using the NO synthase inhibitor NG-nitro-L-arginine methyl
ester (L-NAME, 300μM, present throughout). To establish4 PPAR Research
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Figure 3: The eﬀects of the PPARγ antagonist GW9662 (1μM, (a), and (b)) and the protein synthesis inhibitor, cycloheximide (10μM, (c),
and (d)) on vasorelaxation to anandamide and NADA. Data are given as means with error bars representing SEM.
whether endocannabinoids cause increased expression of
superoxide dismutase (SOD) activity, some experiments
were performed in the presence of the SOD inhibitor
diethyldithiocarbamate (DETCA, 3mM), added 30 minutes
prior to precontraction of arteries.
To assess whether the actions of endocannabinoids
are due to their breakdown to other biologically active
c ompoundsthatma yactatPP ARγ,somevesselsweretreated
with the FAAH inhibitor, URB597 (1μM, added 10 minutes
prior to precontraction).
2.2. Statistical Analysis. In each protocol, the number of
animals in each group is represented by n,a n dv a l u e s
a r ee x p r e s s e da sm e a n± SEM. The diﬀerence between
endocannabinoid-treated and vehicle-treated vessels (adja-
centsegmentsfromthesameaorta)undereachexperimental
protocol were analysed by paired Student’s t-test.
2.3. Drugs. All drugs were supplied by Sigma Chemical
Co. (UK) except where stated. Anandamide, NADA, PEA,
AM251, AM630, and GW9662 were obtained from Tocris
(UK). L-NAME, DETCA, and cycloheximide were dissolved
in the Krebs-Henseleit solution. Anandamide, NADA, PEA,
andURB597weredissolvedinethanolat10mMwithfurther
dilutions made in distilled water. AM251, AM630, and
GW9662 were dissolved in DMSO to 10mM, with further
dilutions in distilled water.
3. Results
3.1. Time-Dependent Vasorelaxant Eﬀects of Endocanna-
binoids. Anandamide (5μM) caused signiﬁcant time-
dependent relaxation of the rat aorta compared to vehicle-
treated arteries at all time-points over the course of 2 hours
(2 hours, vehicle 21 ± 5% versus AEA 51 ± 8% relaxation,PPAR Research 5
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Figure4:Theeﬀectsofremovingtheendothelium((a),(b)),inhibitingnitricoxidesynthase(L-NAME,300μM,(c),and(d)),andinhibiting
superoxide dismutase (DETCA, 3mM, (e), and (f)) on vasorelaxation to anandamide and NADA. Data are given as means with error bars
representing SEM. (∗P<. 05, Student’s t-test).6 PPAR Research
n = 12, P < .01, see Figure 1(a)). NADA (10μM) also
caused signiﬁcant time-dependent relaxation of the rat aorta
compared to vehicle control at all time-points studied over
the course of 2 hours (2 hours, vehicle 19 ± 4% versus
NADA 38 ± 7% relaxation, n = 12, P < .01, see Figure 1(b)).
By contrast, PEA (10μM) did not have any signiﬁcant eﬀect
on the rat aorta compared to vehicle (2 hours, vehicle 20 ±
5% versus PEA 17 ± 9% relaxation, n = 12, Figure 1(c)).
3.2. Receptor Sites of Action. In the presence of the cannabi-
noid CB1 receptor antagonist, AM251 (1μM), the vasore-
laxant response to anandamide was not aﬀected (2 hours,
vehicle 16 ± 4% versus AEA 50 ± 5% relaxation, n = 9, P
< .01, Figure 2(a)). By contrast, in the presence of AM251,
the vasorelaxant response to NADA was abolished (2 hours,
vehicle 12 ± 4% versus NADA 21 ± 6% relaxation, n =
9, nonsigniﬁcant, Figure 2(b)). The CB2 receptor antagonist
AM630 (1μM) did not aﬀect the vasorelaxant response to
eitheranandamide(2hours,vehicle10±3%versusAEA36 ±
5%relaxation,n =9,P <.05,Figure 2(c))orNADA(2hours,
vehicle 12 ± 2% versus NADA 31 ± 5% relaxation, n = 8, P
< .05, Figure 2(d)). In the presence of the PPARγ receptor
antagonist GW9662 (1μM), the vasorelaxant eﬀects of both
anandamide (2 hours, vehicle 26 ± 4% versus AEA 32 ± 5%
relaxation, n = 12, nonsigniﬁcant, Figure 3(a))a n dN A D A( 2
hours, vehicle 25 ± 4% versus NADA 23 ± 3% relaxation, n
= 9, nonsigniﬁcant, Figure 3(b)) were abolished.
3.3. Mechanisms of Action. In the presence of the protein
synthesis inhibitor, cycloheximide (10μM), the vasorelaxant
eﬀects of both anandamide (2 hours, vehicle 20 ± 6% versus
AEA 25 ± 4% relaxation, n = 8, nonsigniﬁcant, Figure 3(c))
and NADA (2 hours, vehicle 4 ± 4% versus NADA 14 ± 3%
relaxation,n=9,nonsigniﬁcant,Figure 3(b))wereabolished.
Removal of the endothelium limited the vasorelax-
ant eﬀects of anandamide such that arteries treated with
anandamide were signiﬁcantly diﬀerent from vehicle-treated
arteries only at 105 and 120 minutes (2 hours, vehicle
11 ± 3% versus AEA 29 ± 6% relaxation, n = 11, P <
.05, see Figure 4(a)). Similarly, removal of the endothelium
limited the vasorelaxant response to NADA (2 hours, vehicle
10 ± 3% versus AEA 24 ± 6% relaxation, n = 9, P < .05,
see Figure 4(b)). The NOS inhibitor, L-NAME (300μM),
inhibited the vasorelaxant response to anandamide (2 hours,
vehicle 16 ± 5% versus AEA 31 ± 8% relaxation, n = 11,
nonsigniﬁcant, Figure 4(c)) and NADA (2 hours, vehicle 6 ±
1% versus NADA 15 ± 5% relaxation, n = 8, nonsigniﬁcant,
Figure 4(c)). Similarly, the SOD inhibitor, DETCA (3mM)
abolished the vasorelaxant response to both anandamide (2
hours, vehicle 20 ± 4% versus AEA 20 ± 8% relaxation,
n = 8, nonsigniﬁcant, Figure 4(e)) and NADA (2 hours,
vehicle 24 ± 4% versus NADA 22 ± 3% relaxation, n = 8,
nonsigniﬁcant, Figure 4(f)).
3.4. Endocannabinoid Metabolism. The presence of the
FAAH inhibitor, URB597 (1μM) did not aﬀect the vasore-
laxant eﬀect of anandamide (2 hours, vehicle 13 ± 2% versus
AEA 36 ± 6% relaxation, n = 10, P < .01, Figure 5(a)),
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Figure 5: The eﬀects of the FAAH inhibitor, URB597 (1μM) on
vasorelaxation to (a) anandamide, (b) NADA, and (c) PEA. Data
are given as means with error bars representing SEM. (∗P<. 05,
∗∗P<. 01, Student’s t-test).PPAR Research 7
and did not alter the vascular response to PEA (2 hours,
vehicle 10 ± 2% versus PEA 18 ± 4% relaxation, n =
7, nonsigniﬁcant, Figure 5(c)). URB597 did inhibit the
vasorelaxantresponsetoNADAsuchthatNADA-treatedand
vehicle-treated arteries were signiﬁcantly diﬀerent at 2 hours
only (2 hours, vehicle 12 ± 2% versus NADA 21 ± 3%
relaxation, n = 9, P < .05, Figure 5(b)).
4. Discussion
In the present study, we have examined whether endo-
cannabinoids cause time-dependent, PPARγ-mediated vas-
cular eﬀects as previously shown for the phytocannabinoid,
THC [13, 19]. In these studies, we demonstrate for the ﬁrst
time that the endocannabinoids anandamide and NADA
cause PPARγ-mediated, time-dependent vasorelaxation of
rat aortae, which is dependent on de novo protein synthesis,
nitric oxide production and superoxide dismutase activity.
These are similar mechanisms to those found to underlie the
vasorelaxanteﬀectsofthePPARγ agonists,rosiglitazone[26],
and THC [13].
On the basis that PPARγ agonists cause time-dependent
vasorelaxation of isolated aortae [13, 26], and that endo-
cannabinoids activate PPARγ [14–18], we investigated
whether endocannabinoids produce time-dependent vasore-
laxation. The endocannabinoids chosen were anandamide
and NADA, both previously demonstrated to activate PPARγ
[14, 16–18], and PEA, which activates PPARα but not PPARγ
[10]. We found that, like rosiglitazone and THC, anan-
damide and NADA produced a slowly developing decrease
in tone of precontracted aortae that was signiﬁcantly greater
than that seen in vehicle-treated segments of the same
artery. The vascular response to anandamide and NADA
was inhibited by the PPARγ antagonist, GW9662, and by
inhibition of de novo protein synthesis. In contrast, PEA did
notcausevasorelaxationoftherataorta.Thisisinagreement
withourpreviousﬁndingthatthePPARαligand,bezaﬁbrate,
does not cause time-dependent vasorelaxation of isolated
aortae [13]. These results demonstrate that PPARγ-, but
not PPARα-active endocannabinoids cause time-dependent
vascular eﬀects.
Some of the vasorelaxant eﬀects of cannabinoids are due
to activation of other target sites such as the CB1 or CB2
receptor [27], and we explored whether the vasorelaxant
response to endocannabinoids might be partially mediated
by any of these. We found that neither the CB1 nor CB2
receptor antagonists had any signiﬁcant eﬀect on vasore-
laxation to anandamide. However, vasorelaxation to NADA
was inhibited by the CB1 receptor antagonist, AM251. It
is possible, therefore, that NADA may activate cannabinoid
receptors at the cell surface, initiating intracellular signalling
that may lead to PPARγ activation. For example, it has
been shown that statins activate PPARs through activation
of extracellular signal-regulated kinase (ERK)1/2 and p38
mitogen-activated protein kinase (MAPK) [28]. Both of
these pathways can be activated by cannabinoid receptor
activation [29, 30].
Further analysis of the time-dependent vasorelaxant
eﬀects of anandamide and NADA showed that these
responses are partially endothelium-dependent and NO-
dependent, as previously demonstrated for rosiglitazone and
THC [13, 26]. We have also previously demonstrated that
the PPARγ-mediated vascular eﬀects of cannabinoids are
due to increases in SOD activity [13, 19]. Similarly, in the
presentstudy,thetime-dependenteﬀectsofanandamideand
NADA were abolished in the presence of a SOD inhibitor,
DETCA, suggesting the vasorelaxant eﬀects of anandamide
and NADA are mediated by upregulation of SOD, preventing
NOofbeingscavengedbyendogenoussuperoxides.Thisisin
agreementwithotherworkshowingPPARγ ligandscausethe
induction of Cu/Zn-SOD [20], and with numerous studies
that have shown that PPARγ ligands increase NO production
and bioavailability in vitro and in vivo [31–34].
There are several potential mechanisms by which
cannabinoids can activate PPARγ including direct binding,
metabolism to other compounds that activate PPARs, or
via intracellular signalling cascades. To establish whether
endocannabinoids are metabolised into PPARγ-active com-
pounds, we performed some experiments in the presence
of the FAAH inhibitor, URB597. The vasorelaxant eﬀects of
anandamide were not aﬀected by URB597, which is consis-
tent with previous studies showing that anandamide directly
binds to PPARγ [16, 17]. It also suggests that prolonging
the eﬀects of anandamide by preventing its breakdown does
not enhance the PPARγ-mediated vasorelaxant response. By
contrast, the vasorelaxant eﬀects of NADA were inhibited
by URB597, suggesting that it is the conversion of this
compound to PPARγ-active metabolites that mediate the
eﬀects of NADA. There are no data presently available
demonstrating a direct interaction between NADA and the
PPARγ ligand binding domain.
In summary, these data provide evidence for the ﬁrst
time that the endocannabinoids anandamide and NADA,
but not the related acylethanolamide PEA, activate PPARγ
in the vasculature, leading to NO-dependent vasorelaxation.
PPARγ agonists have a number of positive cardiovascular
eﬀects, which include increased availability of NO, in vivo
reductions in blood pressure and attenuation of atheroscle-
rosis [35–37]. Similarly, endocannabinoids have a number
of beneﬁcial eﬀects on the cardiovascular system such as
cardiac protection [38–40], beneﬁts in hypertension [41,
42], and potential beneﬁts in atherosclerosis [43]. PPARγ
activation by some endocannabinoids may represent a novel
mechanism by which they are involved in the regulation of
the cardiovascular system.
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